Figs Inc vs Synopsys, Inc. — how do they compare? Figs Inc trades at $15.11 (market cap $2.49B), while Synopsys, Inc. trades at $510.17 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 38.3× Figs Inc's market cap, and Figs Inc is more actively traded (5,964,311 versus 3,374,903). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Synopsys, Inc. for 71 Days on average.
| FIGS | SNPS | |
|---|---|---|
Market Cap | $2.49B | $95.39B |
Volume | 5,964,311 | 3,374,903 |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.12 | $534.56 |
52-Week Low | $6.90 | $367.70 |
Typical Hold Time | 33 Days | 71 Days |
Enterprise Value | $2.25B | $102.62B |
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.
Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights AI-driven partnerships with OpenAI and Amazon, boosting growth prospects. Valuation ratios are elevated, with a P/E of 86.87, reflecting high growth expectations. Analyst sentiment is overwhelmingly positive, with a consensus price target of $572.54.
The outlook for SNPS is favorable, driven by AI integration and strategic acquisitions, but risks include high valuation sensitivity and competitive pressures. Revenue growth and margin expansion from new deals present opportunities, though investors should monitor execution risks and market volatility. The stock's proximity to key resistance levels suggests potential for near-term consolidation or breakout.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →